Femasys is trading 6.13% up at $1.73; no specific cause for the move has been established.
- On October 20, Femasys announced a SandsRx Pharmacy partnership to support the FemaSeed launch and fertility portfolio rollout to OB/GYN practices.
- The release disclosed no financial terms and did not link the agreement to the share-price move. Biotech sector strength may be supportive context.